VROCKSTAR

5/10/24 - $pgny - took a look.. not worth it, upside capped

BATS:PGNY   Progyny, Inc.
5/10/24 - vrockstar - took an hour to deeper dive this y'day (as i was forced to having gotten an average entry of ~$24/shr last night). the conclusion here is - you might see a retrace (which is what i was playing), but the story is defn a whole lot more complicated than meets the eye. perhaps on a valuation front, which is what i do, the FCF is practically all generated from stock comp. in a rising tide stock, that's fine and probably should be treated as stock. but in the event the stock is a multi-year or minimally multi-quarter event to re-find deep bids from new interested parties... and the stock is down considerably (look at it vs. the SPY by doing "PGNY/SPX" in your trading view... it is about flat since IPO. At about 15x earnings (as of ~mid 20's stock price), this is objectively probably value if you have more than a 6-9 month timeframe. Is this a unique name? yes. do they make money "yes", is it growing probably 10+% steady state? yes. is the bad news probably mostly priced in/ behind us at this stage "yes". BUT we remain in an environment where the co still still faces political overhangs, women are punting childhood further and esp for a more expensive treatment...

i think the prudent move is to wait until the dust settles. perhaps we end up buying this higher with more visibility - fine - but you don't lose the oppty cost of parking capital in a potentially dead money boat for some time. i don't think we'll see high 20s for at least 3 months. in a risk off scenario the stock will probably test $20. for that reason, i think risk reward is unfortunately too balanced to take a high conviction stake here and would rather focus my attention elsewhere. exited for a micro-loss and moving on. gl to all who know the stock better and are involved. be safe everyone.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.